<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04078802</url>
  </required_header>
  <id_info>
    <org_study_id>RambamMD</org_study_id>
    <nct_id>NCT04078802</nct_id>
  </id_info>
  <brief_title>0050-19-RMB CTIL - VNOTES Compared to VH for Vaginal Apex Prolapse</brief_title>
  <official_title>Transvaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) Compared With Traditional Vaginal Utero-sacral Ligament Suspension for Vaginal Apex Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      VNOTES (Transvaginal natural orifice transluminal endoscopic surgery) is a relatively new
      surgery for Hysterectomy and Uterosacral ligament suspension to treat Vaginal prolapse. The
      investigators wish to run a randomized control trial comparing it to classic Vaginal
      hysterectomy for the same indication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will recruit 60 women with indication for surgery to treat uterine
      prolapse. 30 women will undergo VNOTES surgery and 30 women will undergo classic vaginal
      hysterectomy. The investigators will compare outcomes of the surgeries such as surgery time,
      bleeding and clinical outcomes after 3 and 6 months post operation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>surgery time</measure>
    <time_frame>from admission up to 6 hours post operation</time_frame>
    <description>time of surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bleeding</measure>
    <time_frame>from admission up to 6 hours post operation</time_frame>
    <description>bleeding at surgery - volume of blood loss estimated by the surgeon performing the operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital days</measure>
    <time_frame>from admission up to 96 hours post operation</time_frame>
    <description>how many days after surgery for hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PISQ12 score - Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire</measure>
    <time_frame>from admission up to 6 hours post operation</time_frame>
    <description>Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire is a scoring index used to measure sexual function of women affected by pelvic organ prolapse. range 0-48. 0 marks good sexual function and 48 measures sexual disability affected from pelvic organ prolapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFDI score - Pelvic Floor Disability Index</measure>
    <time_frame>from admission up to 6 hours post operation</time_frame>
    <description>The Pelvic Floor Disability Index is an index used to obtain an objective score regarding pelvic floor disability comprising of bowel, bladder, or pelvic symptoms over the last 3 months prior to answering the questionnaire. score ranges 0-300. 0 outcome is no pelvic floor disability and 300 marks a high level of pelvic floor disability.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Vaginal Prolapse</condition>
  <arm_group>
    <arm_group_label>VNOTES ARM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment of Vaginal prolapse with VNOTES surgery and apical suspension to the uterosacral ligaments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal hysterectomy Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment of Vaginal prolapse with classic vaginal hysterectomy surgery and apical suspension to the uterosacral ligaments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>VNOTES/VH</intervention_name>
    <description>same as above</description>
    <arm_group_label>VNOTES ARM</arm_group_label>
    <arm_group_label>Vaginal hysterectomy Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women with vaginal prolapse

          -  capable of having a surgery - assessed by an anesthesiologist

          -  women who approve of having the surgery

        Exclusion Criteria:

          -  BMI over 40

          -  women who have recurrent PID (pelvic inflammatory disease)

          -  women with oncology records
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>only women suffer from vaginal prolapse</gender_description>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omer Mor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Omer Mor, mD</last_name>
    <phone>972546486414</phone>
    <email>omermor23@gmail.com</email>
  </overall_contact>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 2, 2019</study_first_submitted>
  <study_first_submitted_qc>September 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>Omer MOR MD</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Prolapse</mesh_term>
    <mesh_term>Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

